BioXcel Therapeutics, Inc.

As of August 12, 2025, BioXcel Therapeutics, Inc. is considered overvalued and in financial distress, with poor metrics compared to peers and a year-to-date stock return of -49.69%, significantly underperforming the S&P 500's gain of 12.22%.

As of August 14, 2023, BioXcel Therapeutics, Inc. is considered overvalued and risky due to negative financial metrics, including a negative P/E ratio and poor operational ratios, alongside a year-to-date stock performance decline of 72.42%, significantly underperforming the S&P 500.

As of June 2, 2025, the market trend is mildly bearish, indicated by daily moving averages and Bollinger Bands, despite some mixed signals from MACD and RSI across different time frames.

As of March 2022, the management team of BioXcel Therapeutics, Inc. includes Dr. Peter Mueller (Independent Chairman), Mr. Vimal Mehta (President, CEO, Co-Founder), Dr. Krishnan Nandabalan (Co-Founder, Chief Digital Officer), and independent directors Dr. Sandeep Laumas and Dr. Michal Votruba. They are responsible for the company's strategic direction and operations.

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs for psychiatric disorders and rare cancers. As of March 2025, it has a market cap of $9.93 million, with net sales of $0 million and a net profit of -$7 million.

As of Jun 18, BioXcel Therapeutics, Inc. has a market capitalization of 9.93 million, with net sales of 1.85 million and a net profit of -40.06 million over the last four quarters. The company's shareholder's funds were -93.10 million, and total assets amounted to 38.34 million.